Spark Therapeutics Inc. (ONCE)

40.09
NASDAQ : Health Technology
Prev Close 39.28
Day Low/High 38.80 / 40.39
52 Wk Low/High 35.63 / 96.59
Avg Volume 594.30K
Exchange NASDAQ
Shares Outstanding 37.22M
Market Cap 1.54B
EPS -7.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Pfizer Initiates Pivotal Phase 3 Program For Investigational Hemophilia B Gene Therapy

Pfizer Initiates Pivotal Phase 3 Program For Investigational Hemophilia B Gene Therapy

Pfizer Inc. (NYSE:PFE) and Spark Therapeutics (NASDAQ:ONCE) announced today that Pfizer initiated a Phase 3 open-label, multi-center, lead-in study ( NCT03587116) to evaluate the efficacy and safety of current factor IX prophylaxis replacement therapy in...

First Week Of ONCE August 17th Options Trading

First Week Of ONCE August 17th Options Trading

Investors in Spark Therapeutics Inc saw new options begin trading this week, for the August 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ONCE options chain for the new August 17th contracts and identified one put and one call contract of particular interest.

Spark Therapeutics Reaches Analyst Target Price

In recent trading, shares of Spark Therapeutics Inc have crossed above the average analyst 12-month target price of $78.22, changing hands for $78.53/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Spark Therapeutics Reports 2017 Financial Results And Recent Business Progress

Spark Therapeutics Reports 2017 Financial Results And Recent Business Progress

U.S. Food and Drug Administration (FDA) grants breakthrough therapy designation to SPK-8011 for hemophilia A

Short Interest Increases 30% For ONCE

Short Interest Increases 30% For ONCE

The most recent short interest data has been released for the 12/29/2017 settlement date, which shows a 1,115,785 share increase in total short interest for Spark Therapeutics Inc , to 4,833,489, an increase of 30.01% since 12/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

7 Winners and Losers From Biggest Biotech Conference of 2017

7 Winners and Losers From Biggest Biotech Conference of 2017

Here are how some of the conference presenters are performing on the market Wednesday

Spark Therapeutics Stock Sees Short Interest Move 12% Higher

Spark Therapeutics Stock Sees Short Interest Move 12% Higher

The most recent short interest data has been released for the 11/30/2017 settlement date, which shows a 350,261 share increase in total short interest for Spark Therapeutics Inc , to 3,237,358, an increase of 12.13% since 11/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Bluebird Bio Becoming Household Name With This Promising Cancer Treatment

Bluebird Bio Becoming Household Name With This Promising Cancer Treatment

Bluebird Bio stock is flying higher by 20% Monday, following an update of its promising cancer treatments, Jim Cramer said.

Blueprint Medicines and Bluebird Bio Soar on ASH Announcements -- Biotech Movers

Blueprint Medicines and Bluebird Bio Soar on ASH Announcements -- Biotech Movers

Blueprint unveiled new data from its ongoing Phase 1 study of avapritinib in advanced systemic mastocytosis at the 59th American Society of Hematology Annual Meeting.

Spark Therapeutics Presents Preliminary Data On Investigational SPK-8011 Phase 1/2 Dose-escalation Clinical Trial In Hemophilia A At 59th American Society Of Hematology (ASH) Annual Meeting And Exposition

Spark Therapeutics Presents Preliminary Data On Investigational SPK-8011 Phase 1/2 Dose-escalation Clinical Trial In Hemophilia A At 59th American Society Of Hematology (ASH) Annual Meeting And Exposition

Preliminary data as of Dec. 6, 2017, show a 100-percent reduction in annualized bleeding rate (ABR) and 98-percent reduction in annualized infusion rate (AIR) in first four participants

Spark Therapeutics And Pfizer Announce Publication In The New England Journal Of Medicine Of Interim Data From Phase 1/2 Clinical Trial Of Investigational Gene Therapy For Hemophilia B

Spark Therapeutics And Pfizer Announce Publication In The New England Journal Of Medicine Of Interim Data From Phase 1/2 Clinical Trial Of Investigational Gene Therapy For Hemophilia B

Annualized bleeding rate (ABR) among 10 participants was reduced 97 percent following SPK-9001 administration, while factor IX concentrate use collectively was reduced 99 percent by 1.95 million international units (IU) during the 492-week cumulative follow-up period

Three-year Follow-up Phase 3 Data Provide Additional Information On Efficacy, Durability And Safety Of Investigational LUXTURNA™ (voretigene Neparvovec) In Patients With Biallelic RPE65-mediated Inherited Retinal Disease

Three-year Follow-up Phase 3 Data Provide Additional Information On Efficacy, Durability And Safety Of Investigational LUXTURNA™ (voretigene Neparvovec) In Patients With Biallelic RPE65-mediated Inherited Retinal Disease

Data show mean improvement demonstrated at one year post one-time administration maintained through at least three years for original intervention cohort, and two years for crossover cohort, with observation ongoing

Spark Therapeutics And Pfizer Amend License Agreement For Investigational SPK-9001 In Hemophilia B

Spark Therapeutics And Pfizer Amend License Agreement For Investigational SPK-9001 In Hemophilia B

Spark Therapeutics to receive up to an additional $25 million per terms of amendment

FDA Advisory Committee Greenlights First Gene Therapy for Inherited Disorder

FDA Advisory Committee Greenlights First Gene Therapy for Inherited Disorder

Spark Therapeutics gains gene therapy advisory OK for treatment restoring some sight for patients facing eventual blindness.

TheStreet Quant Rating: D (Sell)